2013 ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

By | 2016-11-04T16:58:04+00:00 August 1, 2013|Events, Oncology, Viewpoints|

MAY 31–JUNE 4, 2013, CHICAGO, IL

Focusing on the latest cutting-edge and practice-changing science in oncology, JUICE attended the 2013 Annual Meeting of the American Society of Clinical Oncology. Below you will find an executive summary of core areas, as well as some visual impressions from the Oncology Professionals Hall.

JUICE remains committed to helping you keep current with new findings in the science and treatment of cancer, and we hope that you will find the enclosed information useful.


EXECUTIVE SUMMARY

ASCO 2013 offered a plethora of opportunities to comprehensively address the needs of the oncology community, including pre-annual meeting seminars and a wide range of scientific sessions.

This year’s annual meeting featured a number of highly anticipated clinical trial news around the latest and greatest in the evolution of cancer treatment:

  • The early success and excitement of immunotherapy in the treatment of a number of solid tumors has gained significant momentum with fresh trial results and new entrants in the category
  •  Antibody-drug conjugates continue to wow the scientific community with breakthrough efficacy data that are truly transformative in the prognosis of breast cancer
  • A better understanding of cancer biology, molecular profiling, and genomics is paving the way for better drugs

Please feel free to contact us for a full-length report, which we hold available on request.

ONCOLOGY PROFESSIONALS HALL

The Oncology Professionals Hall is the central hub for connecting oncologists with each other and with the pharmaceutical industry.

Showcasing…

  • The science behind the brands
  • Portfolios and pipelines that underline the ongoing commitment to the category
  • Patient-centricity that embodies personalized medicine and the human aspect of medicine

The exhibit hall of near limitless dimensions had elaborate booths for vendors and pharmaceutical companies. Some booths were dedicated to a specific product rather than a manufacturer. The vast extent of both the exhibit hall as well as the individual booths is consistently the most remarkable characteristic of the experience of attending ASCO, and it is outgrowing itself on an annual basis.

A strong emphasis on “pipeline” was notable throughout the spectrum of competitors—even more than in other categories, a deep pipeline is a critical success factor.

The top players in the field had the largest representation in the exhibit hall, along with the largest portfolios and pipelines to underline their ongoing commitment to the category. Some booths were dedicated rather to a single product than a drugmaker, like Seattle Genetics’ ADCETRIS, which happens to have a history of featuring playful exhibits. Last year the company showcased a larger-than-life–sized cell in which children spontaneously decided to play.

In the following pages, we have captured some of the visually notable moments in the exhibitors hall for various reasons, such as size of booth, high traffic, or “the news buzz.”

Roche Genentech featuring their immunotherapy, a PD-L1 antibody, and glycoengineering of antibodies.

Roche Genentech featuring their immunotherapy, a PD-L1 antibody, and glycoengineering of antibodies.

Novartis Oncology, TASIGNA and AFINITOR wings.

Novartis Oncology, TASIGNA and AFINITOR wings.

Pfizer Oncology.

Pfizer Oncology.

GlaxoSmithKline Oncology.

GlaxoSmithKline Oncology.

TEVA Oncology.

TEVA Oncology.

Eisai Oncology.

Bristol-Myers Squibb Oncology, YERVOY section.

Bristol-Myers Squibb Oncology, YERVOY section.

Seattle Genetics featuring a giant antibody-drug conjugate sculpture made from food cans.

Seattle Genetics featuring a giant antibody-drug conjugate sculpture made from food cans.

LEARN MORE:

http://www.asco.org/

http://www.seattlegenetics.com/adcetris

http://www.gene.com/

http://www.novartisoncology.us/

http://www.pfizer.com/partnering/areas_of_interest/oncology

http://us.gsk.com/

http://us.eisai.com/wps/wcm/connect/Eisai/Home/About+Eisai+Inc/Oncology/

http://www.tevapharm-na.com/our-business/Teva-Oncology.aspx

About the Author:

Florian Brey, MD, PhD

VP, Scientific Strategy/Medical Director

Leave A Comment